Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
Portfolio Pulse from Vandana Singh
Edgewise Therapeutics Inc. (NASDAQ:EWTX) reported promising early results for its heart treatment, EDG-7500, in Phase 1 and Phase 2 trials. The trials showed significant reductions in heart obstruction and heart failure biomarkers without adverse effects, leading to a 39.3% increase in EWTX stock.
September 19, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edgewise Therapeutics' stock surged 39.3% following positive trial results for EDG-7500, a treatment for obstructive hypertrophic cardiomyopathy. The trials showed significant reductions in heart obstruction and heart failure biomarkers without adverse effects.
The positive trial results for EDG-7500, showing significant reductions in heart obstruction and heart failure biomarkers without adverse effects, are likely to boost investor confidence in Edgewise Therapeutics, leading to a significant stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100